---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028724"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:54:12.275661+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B

## Summary
- Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.
- Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).
- Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.
- Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.
- FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M.

## SEC filing metadata
- accession: 0001104659-24-028724
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/0001104659-24-028724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/tm247042d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028724
- JSON: https://secwatch.observer/filing/0001104659-24-028724.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028724.txt

## Key facts
- Earnings Releases
  Natera, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $311.1 million, net income ($0.65) per diluted share, EPS ($0.65) per diluted share.
  - Period: fourth quarter and year ended December 31, 2023
  - Revenue: $311.1 million
  - Net income: ($0.65) per diluted share
  - EPS: ($0.65) per diluted share
  - Result: reported results
  source text: testing , today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. ● Generated total
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/0001104659-24-028724-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.